Jason Menges, PA
Medical · Wichita, KSNPI 1982691242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 847 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 847 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amgen$1K
- Abbott$970
- Dexcom, Inc.$785
- Bayer$653
- plus $8K from 45 others
What the payments were for
- Consulting fees$1751%
- Speaking & faculty fees$1251%
- Food & beverage$14,31497%
- Education$1501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$250
- Prolia$175
- FREESTYLE LIBRE 3$125
- NATPARA (PARATHYROID HORMONE)$125
- MOUNJARO$125
- FARXIGA$125
- Saxenda$125
- Kerendia$108
How this compares
$14,764 in reported general payments places this provider in the 95th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 473 | $555,853 |
| MounjaroTirzepatide | 165 | $179,132 |
| Tresiba Flextouch U-100Insulin Degludec | 191 | $146,301 |
| FarxigaDapagliflozin Propanediol | 117 | $130,587 |
| JardianceEmpagliflozin | 138 | $120,839 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $117,836 |
| Tresiba Flextouch U-200Insulin Degludec | 75 | $109,369 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 87 | $87,624 |
| TrulicityDulaglutide | 69 | $79,298 |
| Humulin R U-500Insulin Regular, Human | 16 | $68,965 |
| RybelsusSemaglutide | 47 | $64,088 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 76 | $45,456 |
| VascepaIcosapent Ethyl | 76 | $44,959 |
| Novolog FlexpenInsulin Aspart | 142 | $41,698 |
| Humalog Kwikpen U-100Insulin Lispro | 75 | $41,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $1,490 | $641,060578 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,481 | $258,430234 claims |
| AstraZenecaFarxiga | $640 | $130,587117 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $329 | $128,050150 claims |
| Antares Pharma, Inc.Xyosted | $293 | $7,24212 claims |
| Sanofi-aventis U.S. LLCLantus | $306 | $7,21429 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $228 | $7,052929 claims |
| AbbVieSynthroid | $291 | $6,62780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 205 medical providers in Kansas.
Other medical in Wichita
- Richard AllenbachWichita$70K
- Kathryn WelchWichita$32K
- Trang BrownleeWichita$11K
- Susan GeorgeWichita$10K
- Andrew OsbeckWichita$9K
- Lisa HarrisWichita$8K
- Christiane YourdonWichita$6K
- Kristen OchsnerWichita$5K
- Kristen WolfWichita$5K
- Christine JohnsonWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.